Markers for the development of early prostate cancer.
Biochemical and genetic changes precede histologically identifiable changes accompanying cell transformation often by months or years. De-expression of the extracellular matrix adhesive glycoprotein tenascin and the cell-to-cell adherent protein E-cadherin have been suggested as markers of early neoplastic change in prostate epithelial cells. Previous studies have been inconclusive, probably due to epitope masking. This study examined 2,378 biopsy cores from 289 prostates using a heat antigen retrieval protocol at low pH to improve the accuracy of detection. Tenascin and E-cadherin de-expression was correlated with purinergic receptor and telomerase-associated protein labelling, as well as prostate-specific antigen (PSA) levels and Gleason scores. E-cadherin was a poor marker, as it was expressed in all lesions except carcinomas of the highest Gleason score. Tenascin was maximally expressed in the extracellular matrix and acinar basement membrane in normal and prostatic intraepithelial neoplasia tissue. In prostate cancer tissue, tenascin expression did not correlate with Gleason score but was significantly de-expressed as purinergic receptor and telomerase-associated protein expression increased. Marked changes in tenascin, telomerase-associated protein, and purinergic receptor expression were apparent before any histological abnormalities were visible by haematoxylin and eosin (H&E) stain, making these potential markers for early and developing prostate cancer. Moreover, the potential increased accuracy of diagnosis of underlying prostate cancer using purinergic receptor translocation (PRT) assessment suggests that PSA levels may be more accurate than has generally been supposed when apparent false negatives arising from H&E-based diagnoses are correctly categorized.
Slater
Michael D
MD
Institute for Biomedical Research, Department of Anatomy and Histology, The University of Sydney, Sydney, NSW 2006, Australia.
Lauer
Christopher
C
Gidley-Baird
Angus
A
Barden
Julian A
JA
D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D015820:Cadherins / Q000032:analysis; D002352:Carrier Proteins / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D011230:Precancerous Conditions / Q000175:diagnosis* / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000032:analysis; D019048:Prostatic Intraepithelial Neoplasia / Q000175:diagnosis* / Q000473:pathology; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology; D016601:RNA-Binding Proteins; D011983:Receptors, Purinergic / Q000032:analysis; D019063:Tenascin / Q000032:analysis
D014408:Biomarkers, Tumor; D015820:Cadherins; D002352:Carrier Proteins; D009363:Neoplasm Proteins; D016601:RNA-Binding Proteins; D011983:Receptors, Purinergic; C104342:TEP1 protein, human; D019063:Tenascin; D017430:Prostate-Specific Antigen